03.18.25 -- Stop Hiring Now! Stay Virtual

Join us on April 15th to explore how the rapid development of COVID vaccines sets a precedent for curative therapies for rare diseases. Learn how CDMOs expedite workflows, streamline manufacturing, and ensure reliable, scalable processes. Discover how supporting analytics and robust strategies accelerate the development, commercialization, and timely delivery of life-changing gene therapies. Click here to learn more.

Developers often aim to cut expenses during development. Discover the long-term outcomes of cost-effective measures like using RUO leukopaks compared to investing in high-quality GMP-grade vectors.

A cost-effective approach with a comprehensive AAV analytical package holds the potential to advance the application of rAAV in cell and gene therapy for the treatment of human diseases.

Uncover how JAG201, an innovative AAV9-based gene therapy, leverages SHANK3's mechanism of action to transform the treatment landscape for patients.

Unlock the full potential of CRISPR-Cas9 gene editing with high-purity Cas9 mRNA, the emerging choice for safer and more efficient genome engineering.

Allogeneic therapies are gaining popularity due to diversity, scalability, and affordability. A partner with innovative solutions can help streamline the path from discovery to commercialization.

Learn how you can stay ahead of the evolving cell and gene therapy landscape by leveraging innovative solutions to support the continued growth and success of therapies in 2025 and beyond.

This innovative approach expands the possibilities of personalized medicine, transforming lives for generations by providing innovative medicines to those in need.

See how a recent expansion into Western Pennsylvania is aiming to enable more biopharmaceutical firms to translate cutting-edge science and research into practical applications.

Consider several groundbreaking gene editing technologies and gain insights into their transformative applications in genetic engineering and therapeutic development.

Explore the common pitfalls encountered in CGT CDMO collaborations, including communication breakdowns, differing regulatory interpretations, and program prioritization challenges.

With the increasing demand for cell and gene therapies, CZ nested vials can help the biopharma industry overcome the challenges of scaling up manufacturing and logistics.

Pharmaceutical labeling demands precision. Ensure accuracy and efficiency in your process, from robust control systems to diverse printing options and comprehensive qualifications.

For all its patient-centered benefits, producing personalized medicine at the point of care has pitfalls that are worth careful consideration.

Explore how shifting demand for oligos and peptides is driving outsourcing relationships and innovation in CDMO partnerships. Join our next Outsourced Pharma Live as we cover best practices for outsourcing these specialized therapeutics, focusing on capacity, regulatory challenges, and technology transfer. Register today to learn about the unique challenges and opportunities in scaling production for these complex molecules.

Accelerate your journey from R&D to cGMP-grade LVV production with POSTmark, reaching scalable, high-quality outcomes in just 6–9 months with greater efficiency and reduced risk.

By outsourcing our flexible, scalable AAV platform — yon can leverage DoE methodology, regulatory expertise, and an experienced CMC team for cost-effective, high-quality results.

Our comprehensive testing package includes assays to detect adventitious agents, assess general characteristics, and ensure compliance with cGMP regulations.

A CDMO that manufactures nucleases at research and cGMP grades can eliminate the need for custom manufacturing runs, simplify the transition to clinical application, and reduce regulatory paperwork.